Circle Urges EU to Revise MiCA Stablecoin Rules 
Coinbase, Circle Stocks Slide as Bank Group Sues OCC Over Crypto Charters 
Flydubai Co-Pilot Tried to Crash Israel-Bound Jet, Netanyahu Says 
Nike Stock Slides as Revenue Miss Clouds Turnaround 
Airbus Spain Workers Approve Deal to End Months of Strikes 
DogeOS Launches Testnet to Bring DeFi Apps to Dogecoin 
Chainalysis AI Traces $387M Bitget Hack in Under 10 Minutes 
Goldman Sachs Names CATL, Zenergy Top China Battery Picks 
Robinhood Stock Nears $114 as Jobs Data Boosts Risk Appetite 
Lynas Shares Slide on A$968 Million Meteoric Resources Deal 
Volvo Cars Drops Full-Year Outlook as China, US Sales Weaken 
AAVE, PUMP, WLD and SKY Rally as Crypto Market Slips 
Sanofi, Regeneron Expand Drug Partnership in $8 Billion Deal 
SoftBank Shares Fall After $10 Billion OpenAI Investment 
Italgas to Buy 22.5% Stake in Portugal’s Floene for €120 Million 
Citi Raises Bitcoin Price Target to $113,000 on ETF Optimism 
Add as a preferred source on Google
NEW YORK, Feb. 27, 2017 -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Stemline Therapeutics, Inc. securities (NASDAQ:STML): (1) pursuant and/or traceable to Stemline’s secondary public offering on or about January 20, 2017; and/or (2) publicly traded on the open market between January 19, 2017 and February 1, 2017, both dates inclusive (the “Class Period”). The lawsuit seeks to recover damages for Stemline investors under the federal securities laws.
To join the Stemline class action, go to http://www.rosenlegal.com/cases-1048.html or call Phillip Kim, Esq. or Kevin Chan, Esq. toll-free at 866-767-3653 or email [email protected] or [email protected] for information on the class action.
NO CLASS HAS YET BEEN CERTIFIED IN THE ABOVE ACTION. UNTIL A CLASS IS CERTIFIED, YOU ARE NOT REPRESENTED BY COUNSEL UNLESS YOU RETAIN ONE. YOU MAY ALSO REMAIN AN ABSENT CLASS MEMBER AND DO NOTHING AT THIS POINT. YOU MAY RETAIN COUNSEL OF YOUR CHOICE.
According to the lawsuit, throughout the Class Period Defendants made false and/or misleading statements and/or failed to disclose that: (1) a cancer patient in a Stemline clinical trial tied to SL-401 died from a severe side effect on January 18, 2017; and (2) as a result, Defendants’ statements about its business, operations, and prospects, were materially false and misleading and/or lacked a reasonable basis at all relevant times. When the true details entered the market, the lawsuit claims that investors suffered damages.
A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than April 4, 2017. If you wish to join the litigation, go to http://www.rosenlegal.com/cases-1048.html or to discuss your rights or interests regarding this class action, please contact Phillip Kim or Kevin Chan of Rosen Law Firm toll free at 866-767-3653 or via email at [email protected] or [email protected].
Follow us for updates on LinkedIn: https://www.linkedin.com/company/the-rosen-law-firm or on Twitter: https://twitter.com/rosen_firm.
Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Contact Information:
Laurence Rosen, Esq.
Phillip Kim, Esq.
Kevin Chan, Esq.
The Rosen Law Firm, P.A.
275 Madison Avenue, 34th Floor
New York, NY 10016
Tel: (212) 686-1060
Toll Free: (866) 767-3653
Fax: (212) 202-3827
[email protected]
[email protected]
[email protected]
www.rosenlegal.com
